checkAd

    DGAP-News  656  0 Kommentare Sangui BioTech International Inc.: Revenues improved in the first quarter of the 2015 financial year


    DGAP-News: Sangui BioTech International Inc. / Key word(s): Interim
    Report
    Sangui BioTech International Inc.: Revenues improved in the first
    quarter of the 2015 financial year

    13.11.2014 / 12:00

    ---------------------------------------------------------------------

    Sangui BioTech: Revenues improved in the first quarter of the 2015
    financial year

    Research and development for preparing and carrying out preclinical trials

    Witten, Germany, November 13, 2014 - For the first quarter (as of September
    30, 2014) of its 2015 financial year Sangui BioTech International, Inc.
    reports revenues from product sales and royalties in the amount of
    USD73,470 (Q1/2013: USD26,527). This is an improvement of 73% as compared
    with the fourth quarter of the previous financial year (as of June 30,
    2014).

    Research and development expenses amounted to USD93,103 (Q1/2014:
    USD36,308). The increase is due to preparing and carrying out preclinical
    trials aimed at demonstrating the functionality of Sangui's technology with
    respect to various indications. The net loss attributable to shareholders
    of the parent company came to USD194,168 (Q1/2013: USD172.202), the cash
    outflow from operations during the quarter amounted to USD207,675 (Q1/2013:
    USD189,860).

    Primarily due to the net loss for the quarter, our stockholders' equity
    decreased by USD75,501 from USD7,276 at June 30, 2014 to a stockholders'
    deficit of USD68,225 at September 30, 2014.

    The complete quarterly report on Form 10-QSB is available at www.sec.gov
    and www.sanguibiotech.com.

    Sangui BioTech International, Inc. ("SGBI") is a holding company the shares
    of which are being traded on the OTCQB venture stage marketplace for early
    stage and developing U.S. and international companies (OTCQB: SGBI).
    Companies are current in their reporting and undergo an annual verification
    and management certification process. Sangui shares also trade on the OTC
    markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its
    purpose is to provide financing and access to the capital markets for the
    enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
    subsidiary of Sangui BioTech International, Inc.

    For more information please contact:

    Joachim Fleing
    Phone: +49 (179) 7963472
    Fax: +49 (2302) 915191
    e-mail: fleing@sangui.de



    ---------------------------------------------------------------------

    13.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a
    service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    ---------------------------------------------------------------------


    296450 13.11.2014


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Sangui BioTech International Inc.: Revenues improved in the first quarter of the 2015 financial year DGAP-News: Sangui BioTech International Inc. / Key word(s): Interim Report Sangui BioTech International Inc.: Revenues improved in the first quarter of the 2015 financial year 13.11.2014 / 12:00 …